Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.99
WST's Cash-to-Debt is ranked lower than
60% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.55 vs. WST: 0.99 )
Ranked among companies with meaningful Cash-to-Debt only.
WST' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.24 Max: 0.99
Current: 0.99
0
0.99
Equity-to-Asset 0.67
WST's Equity-to-Asset is ranked higher than
59% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.61 vs. WST: 0.67 )
Ranked among companies with meaningful Equity-to-Asset only.
WST' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35  Med: 0.49 Max: 0.67
Current: 0.67
0.35
0.67
Debt-to-Equity 0.19
WST's Debt-to-Equity is ranked higher than
61% of the 140 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.31 vs. WST: 0.19 )
Ranked among companies with meaningful Debt-to-Equity only.
WST' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.17  Med: 0.53 Max: 1.09
Current: 0.19
0.17
1.09
Interest Coverage 26.20
WST's Interest Coverage is ranked lower than
54% of the 135 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 40.83 vs. WST: 26.20 )
Ranked among companies with meaningful Interest Coverage only.
WST' s Interest Coverage Range Over the Past 10 Years
Min: 5.4  Med: 7.99 Max: 26.2
Current: 26.2
5.4
26.2
Piotroski F-Score: 6
Altman Z-Score: 9.46
Beneish M-Score: -2.51
WACC vs ROIC
8.68%
14.60%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 13.57
WST's Operating Margin % is ranked higher than
76% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.15 vs. WST: 13.57 )
Ranked among companies with meaningful Operating Margin % only.
WST' s Operating Margin % Range Over the Past 10 Years
Min: 8.21  Med: 10.07 Max: 13.57
Current: 13.57
8.21
13.57
Net Margin % 11.42
WST's Net Margin % is ranked higher than
75% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.28 vs. WST: 11.42 )
Ranked among companies with meaningful Net Margin % only.
WST' s Net Margin % Range Over the Past 10 Years
Min: 5.91  Med: 6.91 Max: 11.42
Current: 11.42
5.91
11.42
ROE % 15.26
WST's ROE % is ranked higher than
78% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.37 vs. WST: 15.26 )
Ranked among companies with meaningful ROE % only.
WST' s ROE % Range Over the Past 10 Years
Min: 9.65  Med: 13.52 Max: 17.69
Current: 15.26
9.65
17.69
ROA % 10.10
WST's ROA % is ranked higher than
81% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.13 vs. WST: 10.10 )
Ranked among companies with meaningful ROA % only.
WST' s ROA % Range Over the Past 10 Years
Min: 5.09  Med: 6.34 Max: 10.1
Current: 10.1
5.09
10.1
ROC (Joel Greenblatt) % 20.98
WST's ROC (Joel Greenblatt) % is ranked higher than
67% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.96 vs. WST: 20.98 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
WST' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 12.75  Med: 17.48 Max: 21.35
Current: 20.98
12.75
21.35
3-Year Revenue Growth Rate 1.60
WST's 3-Year Revenue Growth Rate is ranked lower than
60% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.80 vs. WST: 1.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
WST' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -2.9  Med: 5.1 Max: 17.8
Current: 1.6
-2.9
17.8
3-Year EBITDA Growth Rate 3.30
WST's 3-Year EBITDA Growth Rate is ranked lower than
54% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. WST: 3.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
WST' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -20.3  Med: 6.5 Max: 39.8
Current: 3.3
-20.3
39.8
3-Year EPS without NRI Growth Rate 6.80
WST's 3-Year EPS without NRI Growth Rate is ranked higher than
60% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.20 vs. WST: 6.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
WST' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -38.6  Med: 7.1 Max: 73.1
Current: 6.8
-38.6
73.1
GuruFocus has detected 4 Warning Signs with West Pharmaceutical Services Inc $WST.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» WST's 30-Y Financials

Financials (Next Earnings Date: 2017-10-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

WST Guru Trades in Q3 2016

Jim Simons Sold Out
Ron Baron 2,258,479 sh (-0.70%)
Ken Fisher 1,222,462 sh (-1.08%)
Ruane Cunniff 424,467 sh (-4.19%)
Paul Tudor Jones 12,557 sh (-10.31%)
Columbia Wanger 781,437 sh (-15.46%)
» More
Q4 2016

WST Guru Trades in Q4 2016

Chuck Royce 23,000 sh (New)
Paul Tudor Jones Sold Out
Ken Fisher 1,170,631 sh (-4.24%)
Ron Baron 2,138,775 sh (-5.30%)
Ruane Cunniff 373,781 sh (-11.94%)
Columbia Wanger 606,983 sh (-22.32%)
» More
Q1 2017

WST Guru Trades in Q1 2017

Jim Simons 4,100 sh (New)
Caxton Associates 5,600 sh (New)
Chuck Royce 23,000 sh (unchged)
Ken Fisher 1,124,209 sh (-3.97%)
Columbia Wanger 580,216 sh (-4.41%)
Ron Baron 1,900,845 sh (-11.12%)
Ruane Cunniff 59,742 sh (-84.02%)
» More
Q2 2017

WST Guru Trades in Q2 2017

Eaton Vance Worldwide Health Sciences Fund 59,199 sh (New)
Jim Simons 318,600 sh (+7670.73%)
Chuck Royce 23,000 sh (unchged)
Ken Fisher 1,099,159 sh (-2.23%)
Ron Baron 1,806,120 sh (-4.98%)
Caxton Associates 5,000 sh (-10.71%)
Columbia Wanger 481,547 sh (-17.01%)
Ruane Cunniff 42,794 sh (-28.37%)
» More
» Details

Insider Trades

Latest Guru Trades with WST

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2017-06-30 Reduce -4.98%0.04%$78.61 - $99.44 $ 95.214%1,806,120
Ken Fisher 2017-06-30 Reduce -2.23%$78.61 - $99.44 $ 95.214%1,099,159
Ruane Cunniff 2017-06-30 Reduce -28.37%0.01%$78.61 - $99.44 $ 95.214%42,794
Ron Baron 2017-03-31 Reduce -11.12%0.11%$79.58 - $87.7 $ 95.2114%1,900,845
Ken Fisher 2017-03-31 Reduce -3.97%0.01%$79.58 - $87.7 $ 95.2114%1,124,209
Ruane Cunniff 2017-03-31 Reduce -84.02%0.25%$79.58 - $87.7 $ 95.2114%59,742
Ron Baron 2016-12-31 Reduce -5.30%0.05%$70.57 - $85.3 $ 95.2121%2,138,775
Ken Fisher 2016-12-31 Reduce -4.24%0.01%$70.57 - $85.3 $ 95.2121%1,170,631
Ruane Cunniff 2016-12-31 Reduce -11.94%0.04%$70.57 - $85.3 $ 95.2121%373,781
Ron Baron 2016-09-30 Reduce -0.70%0.01%$71.79 - $84.03 $ 95.2120%2,258,479
Ken Fisher 2016-09-30 Reduce -1.08%$71.79 - $84.03 $ 95.2120%1,222,462
Ruane Cunniff 2016-09-30 Reduce -4.19%0.01%$71.79 - $84.03 $ 95.2120%424,467
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NYSE:HRC, NAS:HOLX, NAS:ICUI, NYSE:CMD, NAS:PODD, NYSE:RMD, NYSE:HAE, NYSE:COO, NYSE:HYH, NAS:MMSI, NAS:NXTM, NAS:OSUR, NAS:ATRI, NAS:IRTC, NYSE:GKOS, NAS:LMNX, NAS:LMAT, NAS:ATRC, NAS:ANGO, NAS:XRAY » details
Traded in other countries:WPS.Germany,
Headquarter Location:USA
West Pharmaceutical Services Inc develops, manufactures and sells packaging components and systems for injectable drug delivery, including stoppers and seals for vials, closures and other components used in syringe, and prefillable syringe components.

West Pharmaceutical Services Inc was incorporated under the laws of the Commonwealth of Pennsylvania on July 27, 1923. The Company is a manufacturer of components and systems for the packaging and delivery of injectable drugs as well as delivery system components for the pharmaceutical, healthcare and consumer products industries. Majority of its business is conducted in healthcare markets. Its reportable segments are Proprietary Products and Contract-Manufactured Products. Proprietary Products offers proprietary packaging, containment, and drug delivery products. The packaging products include stoppers and seals for injectable packaging systems, which are designed to help ensure drug compatibility and stability, while also supporting operational efficiency. Proprietary Products also offers syringe and cartridge components, including custom solutions for the specific needs of injectable drug applications. The Company competes with several companies across its product lines. Competition is based mainly on product design and performance, although total cost is becoming increasingly important as pharmaceutical companies continue with aggressive cost control programs across their entire operations. The design, development, manufacturing, marketing, and labeling of certain of the Company's products and its customer's products that incorporate its products are subject to regulation by governmental authorities in the United States, Europe, and other countries, including the FDA and the European Medicines Agency.

Guru Investment Theses on West Pharmaceutical Services Inc

Baron Asset Fund Comments on West Pharmaceutical Services - Jan 30, 2017

Shares of West Pharmaceutical Services, Inc. (NYSE:WST), a manufacturer of packaging components and delivery devices for injectable drugs, gained after reporting impressive quarterly financial results. Management provided solid guidance for 2017 and reaffirmed its goals for strong growth through 2020. We continue to believe that West can double its earnings over the next five years, driven by sales of higher margin packaging components and proprietary products to the pharmaceutical and biotechnology industries.



From Barron Asset Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on West Pharmaceutical Services - Apr 26, 2016

West Pharmaceutical Services, Inc. (NYSE:WST) manufactures components and systems for the packaging and delivery of injectable drugs. West’s shares gained during the quarter after reporting strong financial results and providing solid earnings guidance for 2016. West’s products are frequently “designed in” as part of the regulatory approval process for its clients’ drugs, which makes it quite difficult for West’s products to be displaced throughout a drug’s lifecycle. There is a substantial development pipeline of injectable biologic drugs, and we believe this will allow West to experience double-digit growth rates in its main market for at least the next several years. We also believe that West will benefit from the increased sale of high-margin proprietary products, including newly-developed plastic syringes and wearable injectors for a new generation of high volume, high viscosity drugs. As a result, we believe that company has the potential to double its earnings during the next five years.



From Baron Asset Funds' first quarter 2016 commentary.



Check out Ron Baron latest stock trades

Ratios

vs
industry
vs
history
PE Ratio 40.89
WST's PE Ratio is ranked lower than
69% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.55 vs. WST: 40.89 )
Ranked among companies with meaningful PE Ratio only.
WST' s PE Ratio Range Over the Past 10 Years
Min: 12.28  Med: 23.73 Max: 64.85
Current: 40.89
12.28
64.85
Forward PE Ratio 32.15
WST's Forward PE Ratio is ranked lower than
82% of the 38 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.25 vs. WST: 32.15 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 40.89
WST's PE Ratio without NRI is ranked lower than
69% of the 123 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.55 vs. WST: 40.89 )
Ranked among companies with meaningful PE Ratio without NRI only.
WST' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.28  Med: 23.75 Max: 64.85
Current: 40.89
12.28
64.85
Price-to-Owner-Earnings 80.44
WST's Price-to-Owner-Earnings is ranked lower than
83% of the 83 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.16 vs. WST: 80.44 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
WST' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 20.59  Med: 40.98 Max: 173.32
Current: 80.44
20.59
173.32
PB Ratio 5.70
WST's PB Ratio is ranked lower than
74% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.29 vs. WST: 5.70 )
Ranked among companies with meaningful PB Ratio only.
WST' s PB Ratio Range Over the Past 10 Years
Min: 1.74  Med: 2.94 Max: 6.11
Current: 5.7
1.74
6.11
PS Ratio 4.66
WST's PS Ratio is ranked lower than
62% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.24 vs. WST: 4.66 )
Ranked among companies with meaningful PS Ratio only.
WST' s PS Ratio Range Over the Past 10 Years
Min: 1.02  Med: 1.66 Max: 4.83
Current: 4.66
1.02
4.83
Price-to-Free-Cash-Flow 86.95
WST's Price-to-Free-Cash-Flow is ranked lower than
89% of the 70 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.92 vs. WST: 86.95 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
WST' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 18.49  Med: 51.27 Max: 381.09
Current: 86.95
18.49
381.09
Price-to-Operating-Cash-Flow 29.23
WST's Price-to-Operating-Cash-Flow is ranked lower than
67% of the 91 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.25 vs. WST: 29.23 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
WST' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.55  Med: 12.11 Max: 30.78
Current: 29.23
7.55
30.78
EV-to-EBIT 33.43
WST's EV-to-EBIT is ranked lower than
70% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.41 vs. WST: 33.43 )
Ranked among companies with meaningful EV-to-EBIT only.
WST' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.2  Med: 19.3 Max: 53.3
Current: 33.43
11.2
53.3
EV-to-EBITDA 23.29
WST's EV-to-EBITDA is ranked lower than
63% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.62 vs. WST: 23.29 )
Ranked among companies with meaningful EV-to-EBITDA only.
WST' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.6  Med: 12.2 Max: 27.6
Current: 23.29
7.6
27.6
EV-to-Revenue 4.58
WST's EV-to-Revenue is ranked lower than
59% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.43 vs. WST: 4.58 )
Ranked among companies with meaningful EV-to-Revenue only.
WST' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.3  Med: 1.9 Max: 4.9
Current: 4.58
1.3
4.9
PEG Ratio 5.89
WST's PEG Ratio is ranked lower than
71% of the 66 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.72 vs. WST: 5.89 )
Ranked among companies with meaningful PEG Ratio only.
WST' s PEG Ratio Range Over the Past 10 Years
Min: 1.01  Med: 2.31 Max: 50.27
Current: 5.89
1.01
50.27
Shiller PE Ratio 65.86
WST's Shiller PE Ratio is ranked lower than
69% of the 49 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.16 vs. WST: 65.86 )
Ranked among companies with meaningful Shiller PE Ratio only.
WST' s Shiller PE Ratio Range Over the Past 10 Years
Min: 19.08  Med: 34.99 Max: 68.23
Current: 65.86
19.08
68.23
Current Ratio 2.48
WST's Current Ratio is ranked lower than
52% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.69 vs. WST: 2.48 )
Ranked among companies with meaningful Current Ratio only.
WST' s Current Ratio Range Over the Past 10 Years
Min: 1.37  Med: 2.1 Max: 3.1
Current: 2.48
1.37
3.1
Quick Ratio 1.75
WST's Quick Ratio is ranked lower than
51% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. WST: 1.75 )
Ranked among companies with meaningful Quick Ratio only.
WST' s Quick Ratio Range Over the Past 10 Years
Min: 0.85  Med: 1.51 Max: 2.28
Current: 1.75
0.85
2.28
Days Inventory 71.67
WST's Days Inventory is ranked higher than
84% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 127.43 vs. WST: 71.67 )
Ranked among companies with meaningful Days Inventory only.
WST' s Days Inventory Range Over the Past 10 Years
Min: 52.45  Med: 64.65 Max: 71.67
Current: 71.67
52.45
71.67
Days Sales Outstanding 57.29
WST's Days Sales Outstanding is ranked higher than
67% of the 158 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.12 vs. WST: 57.29 )
Ranked among companies with meaningful Days Sales Outstanding only.
WST' s Days Sales Outstanding Range Over the Past 10 Years
Min: 41.76  Med: 47.63 Max: 57.29
Current: 57.29
41.76
57.29
Days Payable 45.91
WST's Days Payable is ranked lower than
65% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.69 vs. WST: 45.91 )
Ranked among companies with meaningful Days Payable only.
WST' s Days Payable Range Over the Past 10 Years
Min: 29.33  Med: 39.47 Max: 46.32
Current: 45.91
29.33
46.32

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.55
WST's Dividend Yield % is ranked lower than
79% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.17 vs. WST: 0.55 )
Ranked among companies with meaningful Dividend Yield % only.
WST' s Dividend Yield % Range Over the Past 10 Years
Min: 0.52  Med: 1.17 Max: 2.01
Current: 0.55
0.52
2.01
Dividend Payout Ratio 0.22
WST's Dividend Payout Ratio is ranked higher than
74% of the 94 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.30 vs. WST: 0.22 )
Ranked among companies with meaningful Dividend Payout Ratio only.
WST' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.22  Med: 0.27 Max: 0.35
Current: 0.22
0.22
0.35
3-Year Dividend Growth Rate 8.40
WST's 3-Year Dividend Growth Rate is ranked higher than
51% of the 63 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.40 vs. WST: 8.40 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
WST' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 1  Med: 7 Max: 13.7
Current: 8.4
1
13.7
Forward Dividend Yield % 0.59
WST's Forward Dividend Yield % is ranked lower than
81% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.35 vs. WST: 0.59 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.78
WST's 5-Year Yield-on-Cost % is ranked lower than
75% of the 186 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.44 vs. WST: 0.78 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
WST' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.74  Med: 1.66 Max: 2.85
Current: 0.78
0.74
2.85
3-Year Average Share Buyback Ratio -1.40
WST's 3-Year Average Share Buyback Ratio is ranked higher than
62% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -4.00 vs. WST: -1.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
WST' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.3  Med: -1 Max: 4.8
Current: -1.4
-4.3
4.8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 60.26
WST's Price-to-Net-Current-Asset-Value is ranked lower than
94% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.23 vs. WST: 60.26 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
WST' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 59.44  Med: 138.64 Max: 2007.33
Current: 60.26
59.44
2007.33
Price-to-Tangible-Book 6.33
WST's Price-to-Tangible-Book is ranked lower than
65% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.71 vs. WST: 6.33 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
WST' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.2  Med: 2.8 Max: 6.87
Current: 6.33
1.2
6.87
Price-to-Intrinsic-Value-Projected-FCF 4.42
WST's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
86% of the 86 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.25 vs. WST: 4.42 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
WST' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.97  Med: 2.07 Max: 4.5
Current: 4.42
0.97
4.5
Price-to-Intrinsic-Value-DCF (Earnings Based) 3.54
WST's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
77% of the 22 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.00 vs. WST: 3.54 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
WST' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.6  Med: 1.47 Max: 8.34
Current: 3.54
0.6
8.34
Price-to-Median-PS-Value 2.80
WST's Price-to-Median-PS-Value is ranked lower than
94% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. WST: 2.80 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
WST' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.36  Med: 0.7 Max: 2.85
Current: 2.8
0.36
2.85
Price-to-Peter-Lynch-Fair-Value 7.59
WST's Price-to-Peter-Lynch-Fair-Value is ranked lower than
96% of the 49 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.48 vs. WST: 7.59 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
WST' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.54  Med: 1.67 Max: 8.3
Current: 7.59
0.54
8.3
Price-to-Graham-Number 3.39
WST's Price-to-Graham-Number is ranked lower than
66% of the 94 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.52 vs. WST: 3.39 )
Ranked among companies with meaningful Price-to-Graham-Number only.
WST' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.96  Med: 1.6 Max: 3.79
Current: 3.39
0.96
3.79
Earnings Yield (Greenblatt) % 3.03
WST's Earnings Yield (Greenblatt) % is ranked higher than
57% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.70 vs. WST: 3.03 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
WST' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.9  Med: 5.2 Max: 8.9
Current: 3.03
1.9
8.9
Forward Rate of Return (Yacktman) % 6.41
WST's Forward Rate of Return (Yacktman) % is ranked lower than
63% of the 94 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.23 vs. WST: 6.41 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
WST' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -3.7  Med: 9.9 Max: 22.1
Current: 6.41
-3.7
22.1

More Statistics

Revenue (TTM) (Mil) $1,544.30
EPS (TTM) $ 2.33
Beta1.12
Short Percentage of Float1.77%
52-Week Range $70.17 - 99.91
Shares Outstanding (Mil)74.00

Analyst Estimate

Dec17 Dec18
Revenue (Mil $)
EPS ($) 2.43 2.93
EPS without NRI ($) 2.43 2.93
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for WST

Headlines

Articles On GuruFocus.com
West Announces Fall Investor Conference Schedule Aug 25 2017 
New Feature: Screening for Companies Using Technical Indicators Aug 10 2017 
West Announces Increase to Quarterly Dividend Jul 20 2017 
West Elects New Director to the Board Jun 01 2017 
West to Present on Biologics Trends at InnoPack Pharma Confex May 30 2017 
Insiders Roundup: Facebook, General Electric, Aetna May 19 2017 
West Announces Quarterly Dividend and Participation in Upcoming Investor Conferences May 15 2017 
West Highlights Company Scientific and Regulatory Expertise at Notable Industry Meetings May 03 2017 
West Announces First-Quarter 2017 Results Apr 27 2017 
West to Host First-Quarter 2017 Conference Call Apr 13 2017 

More From Other Websites
See what the IHS Markit Score report has to say about West Pharmaceutical Services Inc. Sep 14 2017
West Pharmaceutical Services, Inc. – Value Analysis (NYSE:WST) : September 13, 2017 Sep 12 2017
West Pharmaceutical Services, Inc. breached its 50 day moving average in a Bullish Manner : WST-US :... Sep 11 2017
West Announces Fall Investor Conference Schedule Aug 25 2017
West Pharmaceutical Services, Inc. : WST-US: Dividend Analysis : July 19th, 2017 (record date) : By... Aug 24 2017
Edited Transcript of WST earnings conference call or presentation 27-Jul-17 1:00pm GMT Aug 12 2017
West Pharmaceutical Services, Inc. :WST-US: Earnings Analysis: Q2, 2017 By the Numbers : August 2,... Aug 02 2017
West Pharmaceutical misses Street 2Q forecasts Jul 27 2017
West Announces Second-Quarter 2017 Results Jul 27 2017
West Announces Increase to Quarterly Dividend Jul 20 2017
Gerresheimer licenses syringe safety solution from West Jul 17 2017
Dividend Coverage: This Healthcare Company has Raised Dividend for 24 Consecutive Years; Will Trade... Jul 14 2017
West Pharmaceutical Services, Inc. – Value Analysis (NYSE:WST) : July 3, 2017 Jul 03 2017
West Pharmaceutical Services, Inc. breached its 50 day moving average in a Bearish Manner : WST-US :... Jun 30 2017
3 Best Healthcare Dividend Stocks of the 21st Century (So Far) Jun 24 2017
West Elects New Director to the Board Jun 01 2017
West to Present on Biologics Trends at InnoPack Pharma Confex May 30 2017
West Announces Quarterly Dividend and Participation in Upcoming Investor Conferences May 15 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}